Biocon Ltd

- There is no mention of any planned new fundraising through debt or equity in the provided text. - The company highlighted that the major capital investment phase is substantially complete, with focus now on execution and operating leverage. - They emphasized deleveraging as a priority, with all free cash flow planned to reduce net debt further. - Interest cost savings are being realized, with a strengthened balance sheet post-merger. - No big-ticket greenfield expansion or major capex is planned for FY '27, indicating limited immediate need for fresh capital. - The management is monitoring existing debt instruments, such as callable U.S. dollar bonds, but no specific actions on new debt issuance were disclosed.

- The heavy lifting on capital investments is largely behind Biocon; major investment phases are substantially complete. (Page 5) - The Malaysia facility capacity is being doubled for both drug substance and drug product, with drug product line qualification happening currently and drug substance doubling by end of FY '26. (Pages 15-16) - Minor debottlenecking at Bangalore may occur but no large greenfield capex is planned for FY '27 or FY '28. (Page 15) - Future capital allocation focus will be on profitable and sustainable growth, not large new expansions. (Page 19) - Operating leverage and margin improvement is expected through better utilization of existing state-of-the-art facilities. (Pages 16 and 19) - No further major capex beyond Malaysia plant is planned; investments in product development continue. (Page 11 and 19)

- Biosimilars revenue expected to grow as recent launches start scaling, especially in the second half of FY '27 and into FY '28. - Insulin franchise shows strong growth with global sales crossing $300 million; expanded capacity to support further uplift starting H2 FY '27. - U.S. biosimilar business to gain momentum with launches like aflibercept (Yesafili) expected in H2 FY '27. - Generics business to scale up with improvements in profitability driven by higher volume and operating leverage; pipeline includes several upcoming launches. - Operating leverage to improve as capacity utilization rises in both biosimilars and generics. - Overall volume growth is steady, with a strong focus on sustainable and profitable expansion across all geographies. - Margins expected to improve with increased scale and better supply chain efficiencies. - Long-term expectation is balanced growth across North America, Europe, and emerging markets, maintaining roughly 40%, 35%, and 25% mix respectively.

- Biosimilars and generics businesses are expected to scale up meaningfully in FY '27 and FY '28, supporting growth and operating leverage. - Sequential growth in biosimilars revenue noted (12% increase from Q3 to Q4 FY '26), with further ramp-up expected in the second half of FY '27. - Margin improvements anticipated due to better capacity utilization and operating leverage as generics scale. - EBITDA growth and margin expansion expected, building on a 33% YoY EBITDA growth (Q4 FY '26) and a 26% EBITDA margin in biosimilars. - Interest cost savings from deleveraging will enhance profitability and cash generation from FY '27 onward. - Profitably sustainable growth prioritized over rapid market share gains, aiming for consistent margin profile improvement. - Ramp-up from new product launches (e.g., liraglutide, denosumab biosimilars) will contribute to future earnings. - No specific numeric guidance provided; focus on multi-quarter ramp-up and sustained EBITDA growth.

The provided transcript excerpts do not contain specific details regarding the current or expected orderbook or pending orders for Biocon Limited. The discussion mainly focuses on biosimilar sales breakdown, product performance, capacity utilization, financial results, capital expenditure, and strategic priorities. No explicit commentary or quantitative data related to order book or pending orders is mentioned on the available pages. For precise information on the current or expected orderbook or pending orders, please refer to other sections of the full earnings report or investor presentation not included here.